Scrip
Pfizer's oral rheumatoid arthritis drug positive in Phase III trial
08 November 2010
Sukaina Virji
Pfizer's oral JAK 3 inhibitor tasocitinib (CP-690,550) met two out of three primary endpoints in its first Phase III trial, ORAL Solo, as a monotherapy for the treatment of rheumatoid arthritis.
08 November 2010
Sukaina Virji
Pfizer's oral JAK 3 inhibitor tasocitinib (CP-690,550) met two out of three primary endpoints in its first Phase III trial, ORAL Solo, as a monotherapy for the treatment of rheumatoid arthritis.
No hay comentarios:
Publicar un comentario